Premium
Anticoagulation management in primary care: a trial‐based economic evaluation
Author(s) -
Parry David,
Fitzmaurice David,
Raftery James
Publication year - 2000
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2000.02360.x
Subject(s) - medicine , confidence interval , point of care , primary care , clinical endpoint , emergency medicine , randomized controlled trial , health care , cost–benefit analysis , intensive care medicine , cost effectiveness , medline , economic evaluation , family medicine , nursing , risk analysis (engineering) , ecology , pathology , political science , law , economics , biology , economic growth
The demand for anticoagulation management is increasing because of a widening of the indications of treatment. A primary care clinic using near‐patient testing and computer decision support software is one model of care to meet this increased demand. The study aimed to determine the cost and cost‐effectiveness of primary care‐based anticoagulation management in comparison with ‘traditional’ hospital care‐based provision by means of a cost‐effectiveness analysis using data from a Birmingham‐based multicentre randomized controlled trial. The costs per patient per year in primary care were £170 [95% confidence interval (CI) £149–190] vs. £69 (95% CI £57–81). Sensitivity analysis demonstrated that the cost in primary care could be reduced to under £100 per patient per year under plausible changes in the variables. Primary care provides similar levels of control to secondary care for patients on anticoagulation therapy. There is an increased cost of managing patients in primary care and at no point did primary care become a lower cost option than secondary care. Local decision‐makers need to assess the increased cost of primary care anticoagulation management in terms of the potential reductions in high‐cost serious adverse events.